Atreca Inc BCEL:NASDAQ

Last Price$2.47Cboe Previous Close - Real-Time Last Sale as of 4:00PM ET 8/16/22
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$2.23 (100)
Ask (Size)$2.70 (100)
Day Low / HighN/A - N/A
Volume27.00
 

View Biotechnology IndustryPeer Comparison as of 08/16/2022

 

Atreca Inc ( NASDAQ )

Price: $2.47
Change: -0.02 (0.80%)
Volume: 27.00
4:00PM ET 8/16/2022
 
 

UNITY Biotechnology Inc ( NASDAQ )

Price: $1.37
Change: -0.005 (0.36%)
Volume: 230.4 K
4:00PM ET 8/16/2022
 
 

Curis Inc ( NASDAQ )

Price: $1.07
Change: +0.005 (0.47%)
Volume: 8.2 K
3:59PM ET 8/16/2022
 
 

Solid Biosciences Inc ( NASDAQ )

Price: $0.87
Change: +0.04 (4.49%)
Volume: 2.5 K
3:59PM ET 8/16/2022
 
 

Equillium Inc ( NASDAQ )

Price: $2.91
Change: +0.05 (1.75%)
Volume: 40.9 K
3:59PM ET 8/16/2022
 

Read more news Recent News

--Stifel Nicolaus Adjusts Atreca Price Target to $12 From $14, Maintains Buy Rating
12:11PM ET 8/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Atreca Appoints Stephen Gould as Chief Scientific Officer
4:13PM ET 6/16/2022 MT Newswires

Atreca (BCEL) said late Thursday it appointed Stephen Gould as chief scientific officer. Gould comes to Atreca from Genentech where he most recently...

Atreca to Cut Around 33 Jobs to Conserve Cash, Fund Testing of Prospective Cancer Drugs
4:32PM ET 6/01/2022 MT Newswires

Atreca (BCEL) late Wednesday announced a corporate reorganization - including a 25% workforce reduction - that is expected to preserve enough funding to...

Baird Adjusts Atreca's Price Target to $9 From $12, Keeps Outperform Rating
10:22AM ET 5/19/2022 MT Newswires

Atreca (BCEL) has an average rating of buy and price targets ranging from $4 to $25, according to analysts polled by Capital IQ. (MT Newswires covers...

Company Profile

Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA. View company web site for more details
Address835 Industrial Road
San Carlos, California 94070
Phone+1.650.595.2595
Number of Employees85
President, Chief Executive Officer & DirectorJohn A. Orwin
Chief Financial OfficerHerbert C. Cross
Senior Vice President-ResearchDaniel Emerling
Chief Scientific OfficerStephen Gould

Company Highlights

Price Open$2.73
Previous Close$2.49
52 Week Range$1.51 - 7.00
Market Capitalization$78.7 M
Shares Outstanding31.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.91
Beta vs. S&P 500N/A
Revenue$961.0 K
Net Profit Margin-12,073.68%
Return on Equity-75.17%

Analyst Ratings as of 04/08/2022

Buy
9
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset